Cefdinir

Generic Name
Cefdinir
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C14H13N5O5S2
CAS Number
91832-40-5
Unique Ingredient Identifier
CI0FAO63WC
Background

Cefdinir, also known as Omnicef, is a semi-synthetic, broad-spectrum antibiotic belonging to the third generation of the cephalosporin class. It has been proven to be effective for the treatment of common bacterial infections in the ear, sinus, throat, lungs, and skin. Cefdinir was approved by the FDA in 1997 to treat a variety of mild to moderate infections and was initially marketed by Abbvie. Because of its chemical structure, it is effective against organisms that are resistant to first-line cephalosporin therapy due to the production of beta-lactamase enzymes.

Indication

Cefdinir is indicated to treat acute bacterial otitis media, acute maxillary sinusitis, community-acquired (CA) pneumonia, acute bacterial exacerbations of chronic bronchitis, pharyngitis/tonsillitis, and uncomplicated skin and skin structure infections in children and adults.

The organisms susceptible to cefdinir have been listed below in addition to their associated clinical condition that may be treated with cefdinir. Various beta-lactamase producing organisms may be treated, as indicated in certain sections below.

Respiratory

Acute bacterial exacerbations of chronic bronchitis caused by Haemophilus influenzae, Haemophilus parainfluenzae, Streptococcus pneumoniae (penicillin-susceptible only), and Moraxella catarrhalis

Community-acquired pneumonia caused by Haemophilus influenzae, Haemophilus parainfluenzae, Streptococcus pneumoniae (penicillin-susceptible only), and Moraxella catarrhalis

Ear, nose, and throat

Acute bacterial otitis media caused by Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae (penicillin-susceptible only)

Tonsillitis caused by Streptococcus pyogenes

Pharyngitis caused by Streptococcus pyogenes

Acute maxillary sinusitis caused by Haemophilus pneumoniae and Streptococcus pneumoniae (penicillin-susceptible only), and Moraxella catarrhalis

Skin and skin structure infections

Uncomplicated skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes

Associated Conditions
Acute Exacerbation of Chronic Bronchitis (AECB), Acute Exacerbation of Chronic Bronchitis caused by Streptococcus Pneumoniae, Acute Exacerbations of Chronic Bronchitis caused by Haemophilus Influenza, Acute Exacerbations of Chronic Bronchitis caused by Moraxella catarrhalis, Acute exacerbation of chronic bronchitis caused by Haemophilus parainfluenzae, Acute maxillary sinusitis, Acute maxillary sinusitis caused by H. influenzae, Acute maxillary sinusitis caused by M. catarrhalis, Acute maxillary sinusitis caused by Susceptible strains of Streptococcus pneumoniae, Community Acquired Pneumonia (CAP), Community acquired pneumonia caused by Susceptible strains of Streptococcus pneumoniae, Pneumonia due to Haemophilus influenzae (H. influenzae), Streptococcal Pharyngitis, Tonsillitis, Tonsillitis streptococcal, Uncomplicated Skin and Skin Structure Infections, Uncomplicated skin and skin structure infections caused by streptococcus pyogenes, staphylococcus aureus, Acute otitis media caused by M. catarrhalis, Acute otitis media caused by S.pneumoniae, Bacterial otitis media caused by Haemophilus influenzae, Community aquired pneumonia caused by H. parainfluenzae, Community aquired pneumonia caused by M.catarrhalis
Associated Therapies
-

Trial to Evaluate Beta-Lactam Antimicrobial Therapy of Community Acquired Pneumonia in Children

First Posted Date
2016-09-08
Last Posted Date
2021-02-03
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
385
Registration Number
NCT02891915
Locations
🇺🇸

University of Alabama - Children's of Alabama - Infectious Diseases/Virology, Birmingham, Alabama, United States

🇺🇸

University of Louisville School of Medicine - Norton Children's Hospital - Infectious Diseases, Louisville, Kentucky, United States

🇺🇸

Washington University School of Medicine in St. Louis - Infectious Diseases, Saint Louis, Missouri, United States

and more 6 locations

Effectiveness of Oral Antibiotics in the Treatment of Severe Acute Malnutrition

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2009-10-23
Last Posted Date
2011-07-06
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
2700
Registration Number
NCT01000298
Locations
🇲🇼

St. Louis Nutrition Project, Blantyre, Malawi

Safety and Efficacy Study of Cefdinir Oral Suspension, in Pediatric Subjects to Treat Acute Otitis Media

Phase 2
Completed
Conditions
Interventions
First Posted Date
2008-03-27
Last Posted Date
2008-03-27
Lead Sponsor
Abbott
Target Recruit Count
447
Registration Number
NCT00645203

A Study to Compare Cefdinir and Cephalexin for the Treatment of Mild to Moderate Uncomplicated Skin Infections

First Posted Date
2005-10-10
Last Posted Date
2007-10-25
Lead Sponsor
Abbott
Target Recruit Count
380
Registration Number
NCT00234949
© Copyright 2024. All Rights Reserved by MedPath